odium intake is an important determinant of blood pressure (BP). The original DASH-Sodium (Dietary Approaches to Stop Hypertension-Sodium) feeding study demonstrated that decreasing sodium intake for a 4-week period lowered BP in adults with pre-hypertension or hypertension.
Participants
Adult men and women, aged ≥22 years, were recruited into the original DASH-Sodium trial at the 4 clinical centers. All participants had pre-hypertension or stage I hypertension based on an average systolic BP (SBP) (measured at 3 screening visits) of 120 to 159 mm Hg and an average diastolic BP (DBP) of 80 to 95 mm Hg. Excluded were patients with a prior diagnosis of heart disease, renal insufficiency, poorly controlled dyslipidemia, diabetes mellitus, or heart failure. 1 The study also excluded patients using antihypertensive agents, insulin, or drinking >14 alcoholic drinks a week.
Dietary Interventions
Participants were fed either the DASH diet (intervention) or a control diet. The DASH diet (intervention) emphasized fruits, vegetables, and low-fat dairy foods with reduced intake of saturated fat, total fat, and cholesterol. In addition, the DASH diet emphasized whole grains, poultry, fish, and nuts with smaller amounts of red meat, sweets, and sugar-containing beverages. The control diet reflected foods common in a typical American diet. 4 In addition, participants on either the DASH or control diets were fed each of 3 sodium levels: low, medium, and high, which at 2100 kcal provided a target of 50, 100, and 150 mmol of sodium per day, respectively. The high level was designed to reflect the sodium intake of a typical American. Furthermore, sodium intake was adjusted to reflect the total energy requirements of each participant. As a result, larger or more active participants received more food and sodium than smaller or less active participants. A detailed composition of the diets may be found in Table S1 in the online-only Data Supplement.
Participants were provided all of their food, including snacks and meals. The main meal was consumed at the study centers while their remaining food was delivered to participants' homes. Caloric intake was adjusted to keep participants' weights constant throughout the trial. During a 2-week run-in period, all participants ate the high sodium, control diet. They were subsequently randomized to either the DASH or control diet, following a parallel-arm design. These diets were consumed at each of the 3 sodium levels for 30 days in random order according to a crossover design. Sodium levels were separated by, on average, 5-day washout periods during which participants could resume their usual diets. Over 98% of participants completed each of the intervention periods. 
Blood Pressure and Covariate Measurements
The primary outcome of the original DASH-Sodium study was BP, measured with random-zero sphygmomanometers while participants were seated. BP was measured twice during the run-in period, weekly during the first 3 weeks of each of the three 30-day intervention periods, and at 5 clinic visits during the last 9 days (at least 2 during the final 4 days) of each intervention period. A high BP at baseline was defined as having a mean SBP ≥140 mm Hg or DBP ≥90 mm Hg at baseline.
Additional covariates were ascertained via questionnaire, laboratory specimens, and physical examination. Body mass index was derived from measured height and weight.
BP was measured at 3 visits during the screening phase and at 2 visits during the 2-week run-in period; these 5 measurements were averaged to serve as a baseline for this study.
Statistical Analysis
Study population characteristics were described using means (SD) and proportions. When comparing the effect of sodium over time, we determined the mean SBP and DBP at each week by sodium intake level (low, medium, or high) according to diet assignment (DASH versus control) per the study design. Individual means at each week were compared using t tests with 95% confidence intervals calculated for the difference in measures at each week. Furthermore, a test for plateau of effects over time was performed using quadratic terms, which were evaluated with Wald tests.
Trends in SBP or DBP over time were determined via generalized estimating equation regression models with a Huber and White robust variance estimator, 6 which assumed an exchangeable working correlation matrix. Differences in weekly trends were examined with interaction terms between the sodium level and its weekly effect. Analyses were repeated in the subgroup of participants who had hypertension at baseline. In addition, we performed sensitivity analyses using autoregressive working correlation models for within-person correlations. Finally, to remove the possibility of carryover effects, we conducted a sensitivity analysis that used data from the first feeding period alone, following a parallel design.
Analyses were repeated comparing the weekly mean SBP and DBP between the DASH and control diets. As above, t tests with 95% confidence intervals were used to compare weekly means, and generalized estimating equation was used in analyses of trends. Comparisons were repeated in a subgroup with hypertension at baseline.
All analyses were conducted with Stata version 14.0 (Stata Corporation, College Station, TX). Missing data were minimal and evenly distributed throughout dietary interventions and time periods throughout the study (Tables S2 and S3 ).
Results
Baseline characteristics of the 412 study participants are shown in Table 1 . The mean age of participants was 48.2 (SD, 10.0) years, 56.8% were women, 57.9% were black, 38.8% were obese, and 40.8% had hypertension. The mean run-in SBP was 134.8 (9.5) mm Hg and the mean run-in DBP was 86 (4.5) mm Hg.
BP Time Course From Sodium Reduction
Among participants assigned the control diet, the difference in SBP between high-and low-sodium intake was −4.03 (−6.66, −1.39) mm Hg after week 1 and −6.66 (−8.84, −4.47) mm Hg after week 4 (Table 2; Figure 1A ). The mean weekly change in SBP, from week 1 to week 4, on the high sodium diet was −0.04 mm Hg/week versus −0.94 mm Hg/week on the low-sodium diet (P interaction for difference in trends <0.001). With regards to DBP (Table 2 ; Figure 1C ), reducing sodium intake from high to low decreased DBP at week 1 (−0.80 mm Hg; 95% confidence interval: −2.50, 0.89) and to a greater extent at week 4 (−3.43 mm Hg; 95% confidence interval: −4.72, −2.13). The greater magnitude of the difference in DBP at week 4 compared with week 1 was consistent with an increasing trend in DBP reduction from reducing sodium over time (P interaction=0.004).
In contrast, among participants assigned the DASH diet (Table 2 ; Figure 1B) , the reduction in SBP from lowering sodium intake from high to low was virtually the same between weeks 1 and 4 (−3.35 versus −3.20 mm Hg; P interaction=0.56). Similarly, lowering sodium intake from high to low in the context of the DASH diet reduced DBP by week 2 (−1.65 mm Hg), but this effect did not vary over time (week 4 difference, −1.60 mm Hg; P interaction=0.10) ( Table 2 ; Figure 1D ). An examination of the medium sodium level in the groups above showed similar, albeit attenuated, trends among those assigned the control diet (Table 2 ). In the subgroup of the participants with hypertension at baseline (Table 3) , among those assigned the control diet, reducing sodium intake from high to low changed SBP −4.55 mm Hg at 1 week and −8.43 mm Hg at 4 weeks. The weekly trend on the high sodium diet was −0.07 mm Hg/ week versus −1.45 mm Hg/week on the low-sodium diet (P interaction=0.005). Similarly, among those assigned the control diet, reducing sodium intake from high to low changed DBP −1.29 mm Hg at 1 week and −4.57 mm Hg at 4 weeks (P interaction=0.001) with weekly trends of 0.24 mm Hg/week (high) versus −0.85 mm Hg/week (low; P interaction<0.001).
In the subgroup of participants with hypertension at baseline assigned the DASH diet, reducing sodium intake from high to low changed SBP −2.53 mm Hg at 1 week and −5.17 mm Hg at 4 weeks. The weekly trend of change on the high sodium diet was −0.61 mm Hg/week versus −1.16 mm Hg/week on the lowsodium diet, but these trends were not statistically significant (P interaction=0.37). Similarly, among those assigned the DASH diet, reducing sodium changed DBP −0.12 mm Hg (week 1) and −2.45 mm Hg (week 4). Weekly trends in DBP reduction (−0.1 mm Hg/week on high sodium versus −0.89 mm Hg/week on low sodium) were significantly different (P interaction=0.03).
BP Time Course of DASH Versus Control Diet
With regards to the DASH compared with the control diet, reduction in SBP occurred by week 1 (−4.36 mm Hg) and was maintained by week 12 (−3.82 mm Hg; Table S5; Figure 2A ). Trends were curvilinear with an early reduction in SBP reflected by significant quadratic terms (P<0.001 for both control and DASH diets). Similarly, reduction in DBP at week 1 and 12 was −1.07 and −0.99 mm Hg, respectively (Table  S4 ; Figure 2B ). Trends were also curvilinear with P values for quadratic terms being 0.01 for control and <0.001 for the DASH diet. A similar analysis comparing DASH to control over time in the subgroup with hypertension at baseline showed virtually the same results (Table S5) . Although the magnitudes of SBP and DBP reductions were greater among participants with hypertension, the majority of the BP reduction occurred in the first week of the 12-week intervention.
Sensitivity Analyses
Repeating sodium comparisons using an autoregressive type 1 correlation matrix (Table S6 ) slightly attenuated our findings. Similarly, limiting the sodium comparison to the first 4 weeks only, that is, a parallel design, attenuated but did not change our findings. (Table S7) .
Discussion
In the DASH-Sodium feeding study that enrolled a diverse population of individuals with pre-and stage 1 hypertension, we found that in the context of a typical American diet, a low-sodium diet reduced BP at week 1 with no evidence of a plateau at 4 weeks, suggesting that the full effects of sodium reduction may not be entirely achieved within 4 weeks. In contrast, the DASH diet lowered BP compared with control within a week, and its effects appeared to plateau.
Consistent with a preponderance of evidence from other trials, 2,3 the original DASH-Sodium trial demonstrated that lowering sodium lowered BP. 1 However, prior trials of sodium reduction vary substantially with regards to the duration of the intervention, ranging from 4 days to 36 months. 7, 8 Furthermore, few studies reported BP measurements over time allowing for detailed, within-trial examination of the time course of BP change from sodium reduction. Although this study does not identify the duration of intervention needed to achieve the full effect of sodium reduction, it does suggest that 4 weeks may not be sufficient. Interestingly, the effect of sodium reduction on BP over time was not as pronounced in the DASH diet, and further there was no difference in trends between sodium levels over time while on the DASH diet. It is possible that this attenuation is related to the higher potassium content of the DASH diet, 5 which might be responsible, at least in part, for its BP-lowering effects. [9] [10] [11] Because both potassium and sodium are principal drivers of renin-angiotensin system, it may be that there is some redundancy in targeting this pathway by both reducing sodium and increasing potassium. Nevertheless, there was still a reduction in BP from reducing sodium intake in addition to eating more potassium, attesting to the value of combining both strategies to lower BP.
As for the time course of the DASH diet, we documented that the DASH diet lowered BP within 1 week of initiation, and effects were maintained throughout the duration of the study. These findings confirm the suggestion of data published in figures from the original DASH trial.
This study has several important implications for patients, physicians, and researchers. Data on time course are useful for physicians counseling their patients on the adoption of lifestyle interventions. Although early effects can occur, full effects especially for sodium reduction likely do not occur within a month. Similarly, researchers studying the effects of sodium reduction and other interventions on BP might want to extend interventions beyond 4 weeks if a trial is to document the greatest possible effect. Still, reductions in BP before 4 weeks can be detected, but the effect size is smaller than what could occur with a longer intervention.
This study has limitations. First, each sodium period only lasted ≈ 4 weeks. Although our findings are highly relevant for other trials of sodium reduction, many of which were <1 month in duration, 4 weeks is too short for reliably inferring long-term trends. The ideal study, albeit impractical, would span years, if not decades. Hence, these analyses should be viewed as hypothesis generating and do not allow for conclusions about the time course of BP effects beyond 1 month. Similarly, we cannot speculate on the effects of the DASH diet beyond 12 weeks, the total duration of feeding in the DASHSodium trial. Second, the study may not be generalizable to people with conditions associated with salt retention, namely, patients with chronic kidney disease, medication-treated diabetes mellitus, and heart failure; these conditions were exclusion criteria in the DASH-Sodium trial. Last, our study did not have sufficient duration or size to observe clinical events, such as cardiovascular disease or death.
Our study also has important strengths. It used a randomized design with controlled feeding in a diverse population. Follow-up rates were extremely high. Furthermore, isocaloric feeding was used to minimize the effect of weight change on BP. Finally, BP measurements were assessed in triplicate with a standardized protocol nearly weekly. This afforded the opportunity to study the effect of these interventions over time.
Perspectives
In conclusion, in the context of a typical American diet, a low-sodium diet reduced BP with no evidence of plateau at 4 weeks, suggesting that the full effects of sodium reduction may not have been fully achieved by 4 weeks. In contrast, the DASH diet lowers BP compared with control within a week, and its effects seem to plateau. The minimum length of time needed to observe the full effect of sodium reduction on BP should be the subject of future research. 
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